Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.

AIMS To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters. METHODS PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using NONMEM to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications. RESULTS PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h(-1) and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively. CONCLUSIONS A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.

[1]  E. Ludwig,et al.  Population Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Patients with Acute Episodes Associated with Bipolar I Disorder , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  Daniel Weintraub,et al.  Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. , 2006, The New England journal of medicine.

[3]  B. Pollock,et al.  Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. , 2006, British journal of clinical pharmacology.

[4]  N. Yasui-Furukori,et al.  Dose-Dependent Interaction of Paroxetine With Risperidone in Schizophrenic Patients , 2005, Journal of clinical psychopharmacology.

[5]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[6]  G. Kemmler,et al.  Influence of age and gender on risperidone plasma concentrations , 2005, Journal of psychopharmacology.

[7]  W. Koch,et al.  The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. , 2005, The Journal of clinical psychiatry.

[8]  D. Kupfer,et al.  Utility of Sparse Concentration Sampling for Citalopram in Elderly Clinical Trial Subjects , 2004, Journal of clinical pharmacology.

[9]  Stephen B Duffull,et al.  Development of a dosing strategy for enoxaparin in obese patients. , 2003, British journal of clinical pharmacology.

[10]  S. Gupta,et al.  Population analyses of sustained‐release verapamil in patients: Effects of sex, race, and smoking , 2003, Clinical pharmacology and therapeutics.

[11]  Edoardo Spina,et al.  Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: A Clinically Relevant Pharmacokinetic Drug Interaction , 2002, Journal of clinical psychopharmacology.

[12]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[13]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[14]  J. Schwartz,et al.  Race and sex influence clearance of nifedipine: Results of a population study , 2000, Clinical pharmacology and therapeutics.

[15]  M. Bourin,et al.  Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  A. Peer,et al.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man , 1995, Psychopharmacology.

[17]  Ene I. Ette,et al.  Population Pharmacokinetic Modeling: The Importance of Informative Graphics , 1995, Pharmaceutical Research.

[18]  J. Richardson,et al.  A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5‐HT2 and dopamine D2 receptors , 1995, International clinical psychopharmacology.

[19]  G. Mannens,et al.  Absorption, metabolism, and excretion of risperidone in humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[20]  G. Chouinard,et al.  Clinical review of risperidone. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[21]  S. Marder,et al.  Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. , 1993, Journal of pharmaceutical sciences.

[22]  L Aarons,et al.  Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.

[23]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[24]  J. C. Stoof,et al.  Biochemical profile of risperidone, a new antipsychotic. , 1988, The Journal of pharmacology and experimental therapeutics.

[25]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  H. Akaike.  A new look at the statistical model identification , 1974 .

[27]  J. Donovan,et al.  Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice , 2005, Psychopharmacology.

[28]  T. Stroup,et al.  Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (catie) Schizophrenia Trial Send Reprint Requests to Clinical Outcome Measures: Primary Outcome Clinical and Functional Outcomes Table 1. Catie Schizophrenia Trial Centers' Clinical and Func , 2022 .

[29]  J. Lieberman,et al.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. , 2003, Schizophrenia bulletin.

[30]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[31]  E. Perucca,et al.  Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia , 2000, Psychopharmacology.